The Latin America, Middle East and Africa Cell Therapy Market would witness market growth of 31.8% CAGR during the forecast period (2020-2026). Direct cell reprogramming has gained massive attention as a unique therapeutic strategy. This is due to the superior efficacy and security.
A privately-owned company, Fortuna Fix is making efforts to become the first-ever company to begin clinical use of neural stem cells of patients, which will be generated by direct reprogramming for substitution of lost neuronal tissue in case of neurotrauma or neurodegeneration. These ongoing activities would contribute to market development.
With considerable efforts and regulations being deployed to contain the spread of the COVID-19 crisis, the cell therapy market has been influenced to some degree. Improvement in ongoing research is a major concern, as the majority of universities across the world have reduced their enrollment process for clinical trials for all other research activities.
The arrival of modern technologies has encouraged the development of advanced cellular therapies growth. Companies are using the latest technologies with an aim to increase their product offerings and set-up out-licensing or co-development agreements with other bodies to encourage their product development programs.
The Brazil market dominated the LAMEA Non-Stem Cell Market by Country 2019, and would continue to be a dominant market till 2026. The Argentina market would witness a CAGR of 34.6% during (2020 - 2026). Additionally, The UAE market is exhibiting a CAGR of 33.6% during (2020 - 2026).
The Autologous market dominated the Saudi Arabia Cell Therapy Market by Therapy Type 2019, thereby, achieving a market value of $145.2 million by 2026. Additionally, The Allogeneic market is expected to witness highest CAGR of 35% during (2020 - 2026).
Based on Therapy Type, the market is segmented into Autologous and Allogeneic. Based on Therapeutic Area, the market is segmented into Malignancies, Autoimmune Disorders, Musculoskeletal Disorders, Dermatology and Others. Based on End User, the market is segmented into Academic & Research Institutes and Hospitals & Clinics. Based on Cell Type, the market is segmented into Stem Cell, Umbilical Cord-Derived, Adipose-Derived Stem Cell, Non-Stem Cell, Bone Marrow, Blood and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: Cell Therapy Market in LAMEA is expected to register a CAGR of 31.8% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fujifilm Holdings Corporation, Smith & Nephew PLC, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Medipost Co., Ltd., Stemedica Cell Technologies, Inc., NuVasive, Inc., Avantor, Inc., Vericel Corporation, and Pharmicell Co., Ltd.
By Therapy Type
By Therapeutic Area
By End User
By Cell Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
